Introduction
The biology of B7-H3
B7 family proteins
B7 family ligands | Alternative names | Receptor (binding) partners | Effect of ligand-receptor interaction | References |
---|---|---|---|---|
B7-1 | CD80 | CD28, CTLA-4, PD-L1 | Co-stimulatory or Co-inhibitory | |
B7-2 | CD86 | CD28, CTLA-4 | Co-stimulatory or Co-inhibitory | |
B7-DC | PD-L2, CD273 | ??, PD-1 | Co-stimulatory or Co-inhibitory | |
B7-H1 | PD-L1, CD274 | ??, PD-1 | Co-stimulatory or Co-inhibitory | |
B7-H2 | B7RP1, CD275 | ICOS | Co-stimulatory | PMID: 21,530,327 |
B7-H3 | CD276 | ?? | Co-stimulatory or Co-inhibitory | |
B7-H4 | VTCN1, B7x, B7S1 | ??, BTLA | Co-stimulatory or Co-inhibitory | |
B7-H5 | VISTA, Platelet receptor Gi24, SISP1 | ?? | Co-inhibitory | |
B7-H6 | NCR3LG1 | NKp30 | Co-stimulatory effect for NK cells | |
B7-H7 | HHLA2 | CD28H | Co-stimulatory or Co-inhibitory |
Structure of B7-H3
The Cellular Localization of B7-H3
The distribution and expression of B7-H3 in normal tissues and cancer
Regulation of B7-H3 expression
B7-H3 and cancer pathogenesis
B7-H3 and cancer patient outcome
Immunologic functions of B7-H3
Non-immune regulatory functions of B7-H3
B7-H3 and tumor proliferation
B7-H3 Involvement in angiogenesis and cancer cell metabolism
Effect of B7-H3 on tumor treatment resistance
New advances of B7-H3 research
B7-H3 and cancer stem cells
B7-H3 and cellular senescence
B7-H3 and adipose tissue, obesity, and diabetes mellitus
Effects of post-translational modifications on B7-H3
PTMs Residue | PTMS Class | PTM Peptides |
---|---|---|
N91 | N-Glycosylation | ANRTALFPDLLA QGNASL |
N104 | N-Glycosylation | AQGNASLRL |
N189 | N-Glycosylation | TGNVTTSQMANEQGLF |
N215 | N-Glycosylation | RVVLGANGTYSCL |
N322 | N-Glycosylation | PDLLAQGNASLRLQR |
N407 | N-Glycosylation | QGVPLTGNVTTSQMA |
N433 | N-Glycosylation | LRVVLGANGTYSCLV |
S513-p | Phosphorylation | QDGEGEGsKtALQPL |
T515-p | Phosphorylation | GEGEGsKtALQPLkH |
K521-ub | ubiquitination | KtALQPLkHsDskED |
K526-ub | ubiquitination | PLkHsDskEDDGQEI |
Interaction between B7-H3 and microbiota
Identification of B7-H3 Ligand/Receptor and binding partners
Development of B7-H3 targeting drugs for cancer treatment
List of drugs/agents | Mechanisms of Targeting B7-H3 | Status | Cancer types | Company/organization |
---|---|---|---|---|
B7-H3 TriKE(GTB-5550) | Natural Killer (NK)- cell-based therapy/ADCC | Phase I trial scheduled for 2022 | Multiple myeloma | GT BIOPHARMA, Inc |
TAA06 Injection | B7-H3-targeted CAR-T therapy | FDA approved drug (Orphan drug) | Neuroblastoma | PersonGen BioTherapeutics (Suzhou) Co., Ltd |
131I-omburtamab | radiolabeled mAb targeting B7-H3 | FDA approval? | Neuroblastoma | Y-mAbs Therapeutics, Inc |
Autologous B7-H3-CAR T | B7-H3-targeted CAR-T therapy | Phase I | Epithelial Ovarian Cancer | UNC Lineberger Comprehensive Cancer Center |
DS-7300a | B7-H3 Antibody Drug Conjugate (ADC), | Phase II | Extensive-Stage Small Cell Lung cancer (SCLC) | Daiichi Sankyo, Inc |
MGC018/ MGA012 | Anti-B7-H3 Antibody Drug Conjugate | Phase I/II | Advanced Solid tumors | MacroGenics |
DS-7300a | anti-B7H3 antibody | Phase I/II | Advanced Solid Malignant Tumors | Daiichi Sankyo Co., Ltd |
B7-H3-CAR T | B7-H3-targeted CAR-T therapy | Phase I | Recurrent Glioblastoma Multiforme (GBM) | Crystal Mackall, MD, Stanford University |
Neoadjuvant Nivolumab Plus Ipilimumab | Immunotherapy | Phase 1 | Malignant Peripheral Nerve Sheath Tumor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
177Lu-DTPA-omburtamab | Radioimmunotherapy (a radioactive labelling of a murine monoclonal antibody targeting B7-H3 | Phase I/II | Medulloblastoma | Y-mAbs Therapeutics |